Literature DB >> 4852115

Further observations on the cardiotoxicity of isoprenaline during hypoxia.

D G McDevitt, R G Shanks, J G Swanton.   

Abstract

1 In dogs respired with 10% oxygen: 90% nitrogen, only five out of 16 dogs survived repeated intravenous doses of isoprenaline (either 0.5 or 1.0 mug/kg) and only one out of six dogs survived repeated isoprenaline inhalations from a pressurized aerosol.2 In dogs respired with 15% oxygen: 85% nitrogen, five out of six dogs survived repeated intravenous doses of isoprenaline (2.5 mug/kg).3 The fatal response in these animals consisted of a fall in heart rate, arterial and pulse pressures. Sinus rhythm persisted even after the arterial pressure had fallen, though occasionally a slow A-V nodal rhythm or irregular ventricular ectopic beats occurred. Ventricular fibrillation did not occur.4 Eight out of 10 dogs brought to the verge of a fatal response with 10% oxygen: 90% nitrogen and repeated doses of isoprenaline (2.5 mug/kg) were resuscitated by the administration of 100% oxygen and, when necessary, cardiac massage.5 A group of five dogs survived the combined effects of repeated doses of isoprenaline (2.5 mug/kg) and respiration with 10% oxygen: 90% nitrogen when the time interval between doses was 11 min, instead of the usual 5 minutes.6 Control of pH by infusion of sodium bicarbonate did not protect the dogs from the combined effects of hypoxia and repeated isoprenaline challenge.7 After a 60 min period of continuous isoprenaline infusion in dogs breathing room air, only one of 10 dogs survived artificial respiration with 10% oxygen: 90% nitrogen and repeated challenge with intravenous isoprenaline (1.0 mug/kg) at 5 min intervals. At the higher infusion levels of isoprenaline (0.1 and 1.0 mug kg(-1) min(-1)), two dogs out of four died after the hypoxic mixture was started but before any isoprenaline challenge was given.8 The possible relevance of these findings in dogs to the recently observed increase in mortality in young asthmatics is discussed.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4852115      PMCID: PMC1776702          DOI: 10.1111/j.1476-5381.1974.tb09608.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Mutal suppression of cardiovascular effects of some beta-adrenoreceptor agonists in the cat.

Authors:  J M Atkinson; M J Rand
Journal:  J Pharm Pharmacol       Date:  1968-12       Impact factor: 3.765

2.  Isoprenaline resistance and the use of pressurised aerosols in asthma.

Authors:  J W Paterson; M E Conolly; D S Davies; C T Dollery
Journal:  Lancet       Date:  1968-08-24       Impact factor: 79.321

3.  Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols.

Authors:  W H Inman; A M Adelstein
Journal:  Lancet       Date:  1969-08-09       Impact factor: 79.321

4.  A study of the clinical course and arterial blood gas tensions of patients in status asthmaticus.

Authors:  H A Rees; J S Millar; K W Donald
Journal:  Q J Med       Date:  1968-10

5.  Cardiac toxicity of aerosol propellants.

Authors:  G J Taylor; W S Harris
Journal:  JAMA       Date:  1970-10-05       Impact factor: 56.272

6.  Blood concentrations in man of fluorinated hydrocarbons after inhalation of pressurised aerosols.

Authors:  C T Dollery; D S Davies; G H Draffan; F M Williams; M E Conolly
Journal:  Lancet       Date:  1970-12-05       Impact factor: 79.321

7.  The effects of posture, oxygen, isoproterenol and atropine on ventilation-perfusion relationships in the lung in asthma.

Authors:  G B Field
Journal:  Clin Sci       Date:  1967-04       Impact factor: 6.124

8.  Influences of hypoxemia and acidemia on left ventricular function.

Authors:  S E Downing; N S Talner; T H Gardner
Journal:  Am J Physiol       Date:  1966-06

9.  Bronchodilator effect of oral salbutamol in asthmatics treated with corticosteroids.

Authors:  S S Parker; Y F Choo-Kang; E J Cooper; S J Cameron; I W Grant
Journal:  Br Med J       Date:  1971-10-16

10.  Resistance to -adrenoceptor stimulants (a possible explanation for the rise in ashtma deaths).

Authors:  M E Conolly; D S Davies; C T Dollery; C F George
Journal:  Br J Pharmacol       Date:  1971-10       Impact factor: 8.739

View more
  11 in total

Review 1.  Interactions between corticosteroids and beta agonists.

Authors:  D R Taylor; R J Hancox
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

2.  Lack of cardiac or bronchodilator tachyphylaxis to isoprenaline in the dog.

Authors:  H Minatoya; B A Spilker
Journal:  Br J Pharmacol       Date:  1975-03       Impact factor: 8.739

3.  Investigation of occurrence of tolerance to bronchodilator drugs in chronically pretreated guinea-pigs.

Authors:  A A Anderson; G M Lees
Journal:  Br J Pharmacol       Date:  1976-03       Impact factor: 8.739

4.  The effect of anoxia on the ventricular fibrillation threshold in the rabbit isolated heart.

Authors:  M F Murnaghan
Journal:  Br J Pharmacol       Date:  1975-08       Impact factor: 8.739

Review 5.  Risks versus benefits of inhaled beta 2-agonists in the management of asthma.

Authors:  B J Lipworth
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

Review 6.  Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?

Authors:  B J Lipworth; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

Review 7.  Regular treatment with salmeterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

Review 8.  Regular treatment with formoterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 9.  Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

10.  Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.

Authors:  Orlagh O'Shea; Elizabeth Stovold; Christopher J Cates
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.